長期使用替諾福韋酯富馬酸富馬酸酯治療肝炎為抗原陰性的

StephenW

Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B
Bahri Abayli  1 , Cansu Abaylı  1 , Genco Gencdal  2
Affiliations
Affiliations

    1
    Seyhan Devlet Hastanesi, Adana 090, Turkey.
    2
    Department of Gastroenterology, Hepatology and Liver Transplantation, Koc University, School of Medicine, İstanbul 34300, Turkey. [email protected].

    PMID: 33815864 PMCID: PMC8008959 DOI: 10.4292/wjgpt.v12.i2.32

Abstract

Background: Hepatitis B virus is a universal health problem. There are approximately 250 million people living with hepatitis B worldwide, and approximately 600000 of these people die every year due to the virus.

Aim: To compare the pretreatment and post-treatment histopathological results of patients with hepatitis be antigen (HBeAg)-negative chronic hepatitis B (CHB) who had been receiving tenofovir disoproxil fumarate (TDF) treatment at our clinic for at least 5 years.

Methods: Patients with HBeAg-negative CHB who were being treated with TDF (245 mg/d) were included in the study. Liver biopsies of patients before TDF treatment and liver biopsies after 5 years of TDF treatment were retrospectively compared.

Results: A total of 50 HBeAg-negative CHB patients were included in the study (mean age: 47.9 ± 10.4 years, men: 27.54%). Histological improvement was observed in 78% (39) of the patients after 5 years of treatment. After the 5 years of treatment, the mean Ishak score of the patients was 1.3 ± 1.3, and the mean histologic activity index score was 4.1 ± 2.8. A 1.53 point reduction in Ishak fibrosis score was detected after long-term TDF treatment.

Conclusion: Liver biopsies after 5 years of TDF treatment revealed a significant histological response and a regression of the necroinflammatory score compared to pretreatment liver biopsies. To better understand the effects of antiviral treatments on the improvement of liver histology, long-term studies involving larger numbers of patients are needed.

Keywords: Biopsy; Chronic hepatitis; Fibrosis; Hepatitis B; Liver; Tenofovir.

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

StephenW

長期使用替諾福韋酯富馬酸富馬酸酯治療肝炎為抗原陰性的慢性乙型肝炎的組織病理學評價
Bahri Abayli 1，CansuAbaylı1，Genco Gencda​​l 2
隸屬關係
隸屬關係

    1個
    Seyhan Devlet Hastanesi，阿達納090號，土耳其。
    2個
    Koc大學醫學院胃腸病學，肝病學和肝移植系，土耳其伊斯坦布爾34300。 gencogencda​​[email protected]。

    PMID：33815864 PMCID：PMC8008959 DOI：10.4292 / wjgpt.v12.i2.32

抽象的

背景：乙型肝炎病毒是普遍存在的健康問題。全世界約有2.5億人患有乙型肝炎，其中每年約有600000人死於該病毒。

目的：為了比較在我們診所接受替諾福韋二富馬酸富馬酸酯（TDF）治療至少五年的乙型肝炎抗原（HBeAg）陰性的慢性乙型肝炎（CHB）患者的治療前後的組織病理學結果。

方法：本研究包括接受TDF（245 mg / d）治療的HBeAg陰性CHB患者。回顧性比較TDF治療前患者的肝活檢和TDF治療5年後的肝活檢。

結果：本研究共納入50例HBeAg陰性CHB患者（平均年齡：47.9±10.4歲，男性：27.54％）。治療5年後，在78％（39）的患者中觀察到組織學改善。治療5年後，患者的平均Ishak得分為1.3±1.3，平均組織學活動指數得分為4.1±2.8。長期TDF治療後，Ishak纖維化評分降低了1.53分。

結論：與治療前的肝活檢相比，TDF治療5年後的肝活檢顯示出顯著的組織學反應和壞死炎症評分的降低。為了更好地了解抗病毒治療對改善肝組織學的作用，需要涉及大量患者的長期研究。

關鍵字：活檢；慢性肝炎；纖維化;乙型肝炎；肝臟;替諾福韋。

©2021年作者。百世登出版集團有限公司出版。保留所有權利。

StephenW

https://www.wjgnet.com/2150-5349/full/v12/i2/32.htm